Research Paediatric Cancer

Leukaemia and Paediatric Haematology Disorders

Research Program

Paediatric Cancer

Leaders

Where we are

SJD Barcelona Children's Hospital

How to reach us

Related websites

Our group carries out translational research with the aim of applying the advances made in biological diagnosis to healthcare practice and the use of the most innovative treatments in paediatric patients with blood disorders. Since its creation in 2012, our group has obtained uninterrupted funding for competitive and non-competitive calls for public and private aid.

We participate as a clinical group associated with the Hereditary Cancer and Related Syndromes Group in the Centre for Biomedical Network Research on Rare Diseases (CIBERER). The Hereditary Red Blood Cell Disorders Unit, which is part of both SJD Barcelona Children's Hospital and Hospital de la Santa Creu i Sant Pau, will shortly be recognised as a Reference Centre-Service Unit (RCSU).

We have been a consolidated AGAUR research group (Government of Catalonia, references 2014 SGR 1398 and 2017 SGR 1672) since 2014.

Desarrollo de una nueva terapia CAR-T dirigida a CD1a para el tratamiento de leucemias/linfomas de células T CD1a+

Investigador principal: Susana Rives Solà
Convocatoria: proyectos colaboración público-privada
Código: CPP2021-008508
Año inicio: 2022
Año finalización: 2025
Financiador: Ministerio de Ciencia e innovación, Agencia Estatal de investigación
Importe concedido: 510.821,00 €

Proyecto CPPC2021-008508 financiado por MICIN/AEI/10.13039/501100011033 y por la Unión Europea NextGenerationEU/PRTR

Research lines

  1. Acute lymphoblastic leukaemia (ALL).
  2. Acute myeloblastic leukaemia (AML).
  3. Bone marrow failure and myelodysplastic syndromes.
  4. Red blood cell disorders.
  5. Alterations in haemostasis.
  6. Immunotherapy and cell therapy.
  7. Prevention of toxicity secondary to leukaemia treatment.

Scientific objectives

  1. To consolidate our group as a CIBER associated clinical group and define the current situation of paediatric haematology diseases in the context of those considered as "rare diseases".
  2. To promote cooperative strategies to advance biological diagnosis and follow-up of minimal residual disease (MRD) in cases of acute leukaemias and other paediatric haematology disorders. To design and implement new techniques and internal/external quality controls.
  3. To analyse new biomarkers of potential diagnostic, prognostic and therapeutic utility in high-risk paediatric leukaemias.
  4. To promote the applicability of new therapies in paediatric patients by conducting clinical trials. To consolidate the experience of our group in the use of cell therapy with combination antiretroviral therapy (cART) and haematopoietic progenitor transplantation.
  5. To study the biological and clinical factors that could help prevent or alleviate toxicity secondary to leukaemia therapy.
  6. To apply photonics to the diagnosis and monitoring of red blood cell disorders.
  7. To study the risk factors associated with chemotherapy-induced thrombosis in paediatric ALL and establish preventive measures.
  8. To establish genomic precision diagnosis using next-generation sequencing techniques to different paediatric haematology disorders.

Area/Field of expertise

We conduct translational research aimed at the rapid "bench-to-bedside" application of diagnostic and therapeutic innovations relevant to leukaemia and other haematology disorders. Our group includes haematologists, paediatric haematology-oncologists, biologists and lab technicians, with recognised expertise in the diagnosis and treatment of children with haematology disorders. With this multidisciplinary team, we can provide a comprehensive approach to the real problems of patients and conduct research that is readily transmitted to clinical practice.

Since its creation, our group has established itself within the main clinical and biological coordination positions in the area of paediatric haematology disorders. This has enabled us to represent the Spanish group in major international cooperative groups and participate in national and international cooperation projects.

Over the past few years, we have incorporated diagnostic and therapeutic tools and consolidated the harvesting of blood samples in our biobank. This has led to the establishing of the hospital as a reference centre for research into childhood leukaemia and other blood disorders. We deploy various methodologies including complete biological diagnosis and close monitoring of minimal residual disease in acute leukaemia (morphology, flow cytometry, molecular biology, including next-generation sequencing, lymphoid clonality testing, etc.). The incorporation of global haemostasis assays, such as the thrombin generation assay, will enable us to establish normal values and standardise their use in the paediatric population.

This year, the integrated HSJD-HSP unit was granted RSCU accreditation in hereditary RBC disorders.

Group members

Last Publications

More Publications

Projects

Project name:
Análisis de los factores pronósticos de fracaso del tratamiento tras terapia con células T con receptores antigénicos quiméricos (CAR-T) en pacientes pediátricos con leucemia linfoblástica aguda de línea B
Leader
Susana Rives Solà, Montserrat Torrebadell Burriel
Funding entities:
Instituto de Salud Carlos III (ISCIII), Fundació Privada per a la Recerca i la Docència Sant Joan de Déu - FSJD
Code
PI21/00218
Starting - finishing date:
2022 - 2026
Project name:
Desarrollo de una nueva terapia CAR-T dirigida a CD1a para el tratamiento de leucemias/linfomas de células T CD1a+
Leader
Susana Rives Solà
Funding entities:
Ministerio De Ciencia E Innovacion
Code
CPP2021-008508
Starting - finishing date:
2022 - 2025
Project name:
Estudio multicéntrico fase 2 en pacientes pediátricos (0-18 años) con leucemia linfoblástica aguda B CD19+ en recaída o refractaria
Leader
Susana Rives Solà
Funding entities:
Instituto de Salud Carlos III (ISCIII)
Code
ICI21/00033
Starting - finishing date:
2022 - 2025
More projects

Theses

  • Estudi de nous biomarcadors en pacients amb leucèmia pediàtrica d´alt risc
    Author
    Esperanza Cebollada, Elena
    Institution
    UNIVERSIDAD DE BARCELONA
    14/12/2023
  • Estudi de factors clínics i biològics associats a toxicitat en el tractament de la leucèmia limfoblàstica aguda pediàtrica.
    Author
    Mesegue Meda, Montserrat
    Institution
    UNIVERSIDAD DE BARCELONA
    17/05/2023
  • Estudi del perfil d'expressió de les histones deacetilasa (HDAC) en pacients pediàtrics amb leucèmia aguda
    Author
    Vega García, Nerea
    Institution
    UNIVERSIDAD DE BARCELONA
    18/09/2018
More Theses

News

See All news

More activities

More activities